Yazar "Karadurmus, N." seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey(Elsevier Science Inc, 2018) Kilickap, S.; Ozturk, A.; Karadurmus, N.; Korkmaz, T.; Yumuk, P.; Cicin, I.; Paydas, S.; Cilbir, E.; Sakalar, T.; Uysal, M.; Uskent, N.; Demir, N.; Sakin, A.; Turhal, N.; Keskin, S.; Tural, D.; Eralp, Y.; Basal, F.; Yasar, H.; Sendur, M. A.; Demirci, U.; Cubukcu, E.; Karaagac, M.; Karaca, S.; Tatli, A.; Yetisyigit, T.; Urvay, S.; Gursoy, P.; Uluc, B. Oyan; Turna, Z.; Kucukoner, M.; Olmez, O.; Cabuk, D.; Seker, M.; Unal, O.; Meydan, N.; Okutur, S.; Tunali, D.Öğe Immunotherapy for Lung Cancer(Turkiye Klinikleri, 2023) Karadurmus, N.; Akyürek, N.; Aydiner, A.; Savaş, R.; Sönmez, Ö.; Sendur, M.A.N.; Oyan, B.Lung cancer is one of the leading causes of cancer-related deaths in men and women. Similar to the approach with other cancer types, lung cancer staging is crucial in planning an effective treatment plan and predicting patient prognosis. Effective immunotherapies for patients with non-small cell lung cancer and non-genomic driver mutations are rapidly evolving. Moreover, anti-programmed death re-ceptor-1 (PD-1)/programmed death ligand 1 (PD-L1)-based treatments have become the first-line standard of care. Despite shortcomings, PD-L1 expression level seems currently to be a relatively reliable predictor of the clinical efficacy of treatment with anti-PD-1/PD-L1 anti-bodies. However, additional biomarkers are required to better personalize treatment options for these patients. This review aimed to increase awareness of lung cancer and immunotherapy treatment options, depending on patient and disease stage characteristics. © 2023 by Turkish Society of medical oncology.Öğe NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY(Ferrata Storti Foundation, 2017) Ferhanoglu, B.; Bekoz, H.; Karadurmus, N.; Paydas, S.; Gulbas, Z.; Turker, A.; Toptas, T.; Tuglular, T. Firatli; Tekgunduz, E.; Kaya, A. H.; Tastemir, N.; Arat, M.; Tanrikulu, F. Pepedil; Ozkocaman, V.; Abali, H.; Turgut, M.; Kaynar, L.; Karadogan, I.; Ozbalak, M.; Ozcan, M.; Dogu, M. H.; Hacioglu, S. Kabukcu; Yildirim, R.; Barista, I.; Demirkaya, M.; Koseoglu, F. D.; Yuksel, M. Kurt; Sonmez, M.; Toprak, S. K.Öğe Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience(Oxford Univ Press, 2017) Bekoz, H.; Karadurmus, N.; Paydas, S.; Turker, A.; Toptas, T.; Tuglular, T. Firatli; Sonmez, M.; Gulbas, Z.; Tekgunduz, E.; Kaya, A. H.; Ozbalak, M.; Tastemir, N.; Kaynar, L.; Yildirim, R.; Karadogan, I.; Arat, M.; Tanrikulu, F. Pepedil; Ozkocaman, V.; Abali, H.; Turgut, M.; Yuksel, M. Kurt; Ozcan, M.; Dogu, M. H.; Hacioglu, S. Kabukcu; Barista, I.; Demirkaya, M.; Koseoglu, F. D.; Toprak, S. K.; Yilmaz, M.; Demirkurek, H. C.; Demirkol, O.; Ferhanoglu, B.Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey. The median follow-up was 7 months, and the patients had a median of 5 (2-11) previous lines of therapy. Fifty-seven (70%) and 63 (77%) had been treated by stem-cell transplantation and brentuximab vedotin, respectively. Results: Among 75 patients evaluated after 12 weeks of nivolumab treatment, the objective response rate was 64%, with 16 complete responses (CR; 22%); after 16 weeks, it was 60%, with 16 (26%) patients achieving CR. Twenty patients underwent subsequent transplantation. Among 11 patients receiving allogeneic stem-cell transplantation, 5 had CR at the time of transplantation and are currently alive with ongoing response. At the time of analysis, 41 patients remained on nivolumab treatment. Among the patients who discontinued nivolumab, the main reason was disease progression (n = 19). The safety profile was acceptable, with only four patients requiring cessation of nivolumab due to serious adverse events (autoimmune encephalitis, pulmonary adverse event, and two cases of graft-versus-host disease aggravation). The 6-month overall and progression-free survival rates were 91.2% (95% confidence interval: 0.83-0.96) and 77.3% (0.66-0.85), respectively. Ten patients died during the follow-up; one of these was judged to be treatment-related. Conclusions: Nivolumab represents a novel option for patients with cHL refractory to brentuximab vedotin, and may serve as a bridge to transplantation; however, it may be associated with increased toxicity.Öğe Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study(Elsevier, 2021) Arslan, C.; Kefeli, U.; Yildirim, E.; Isikdogan, A.; Karadurmus, N.; Karabulut, B.; Cicin, I.[No Abstract Available]
